Search research articles
Contact Us
Filters
Showing results (11-20 of 61) with videos related to
Page
of 7
Sort By:
Biochemistry
|
October 8, 2003
Insights into a single rod-like helix in activated radixin required for membrane-cytoskeletal cross-linking
Klaus P Hoeflich, Sachiko Tsukita, Leslie Hicks, et al.
Cancer Research
|
April 12, 2013
Pak1 kinase links ErbB2 to β-catenin in transformation of breast epithelial cells
Luis E Arias-Romero, Olga Villamar-Cruz, Min Huang, et al.
Molecular and Cellular Biology
|
September 23, 2015
p21-Activated Kinase 2 Regulates Endothelial Development and Function through the Bmk1/Erk5 Pathway
Maria Radu, Karen Lyle, Klaus P Hoeflich, et al.
European Journal of Biochemistry
|
February 7, 2004
FRET evidence for a conformational change in TFIIB upon TBP-DNA binding
Le Zheng, Klaus P Hoeflich, Laura M Elsby, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
January 17, 2009
Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy
Harvey Wong, Marcia Belvin, Sylvia Herter, et al.
Journal of Molecular Biology
|
January 18, 2006
Characterization of dual substrate binding sites in the homodimeric structure of Escherichia coli mRNA interferase MazF
Guang-Yao Li, Yonglong Zhang, Mitchell C Y Chan, et al.
EJNMMI Research
|
June 2, 2012
FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973
Andreas R Baudy, Taner Dogan, Judith E Flores-Mercado, et al.
Cancer Research
|
July 18, 2008
A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy
Si Tuen Lee-Hoeflich, Lisa Crocker, Evelyn Yao, et al.
Genes & Cancer
|
July 7, 2016
The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase
Klaus P Hoeflich, Jane Guan, Kyle A Edgar, et al.
Oncotarget
|
June 10, 2011
p21-activated kinase 1: PAK'ed with potential
Christy C Ong, Adrian M Jubb, Wei Zhou, et al.
Page
of 7
Search research articles
Search
Showing results (11-20 of 61) with videos related to
Sort By:
Page
of 7
Biochemistry
|
October 8, 2003
Insights into a single rod-like helix in activated radixin required for membrane-cytoskeletal cross-linking
Klaus P Hoeflich, Sachiko Tsukita, Leslie Hicks, et al.
Cancer Research
|
April 12, 2013
Pak1 kinase links ErbB2 to β-catenin in transformation of breast epithelial cells
Luis E Arias-Romero, Olga Villamar-Cruz, Min Huang, et al.
Molecular and Cellular Biology
|
September 23, 2015
p21-Activated Kinase 2 Regulates Endothelial Development and Function through the Bmk1/Erk5 Pathway
Maria Radu, Karen Lyle, Klaus P Hoeflich, et al.
European Journal of Biochemistry
|
February 7, 2004
FRET evidence for a conformational change in TFIIB upon TBP-DNA binding
Le Zheng, Klaus P Hoeflich, Laura M Elsby, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
January 17, 2009
Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy
Harvey Wong, Marcia Belvin, Sylvia Herter, et al.
Journal of Molecular Biology
|
January 18, 2006
Characterization of dual substrate binding sites in the homodimeric structure of Escherichia coli mRNA interferase MazF
Guang-Yao Li, Yonglong Zhang, Mitchell C Y Chan, et al.
EJNMMI Research
|
June 2, 2012
FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973
Andreas R Baudy, Taner Dogan, Judith E Flores-Mercado, et al.
Cancer Research
|
July 18, 2008
A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy
Si Tuen Lee-Hoeflich, Lisa Crocker, Evelyn Yao, et al.
Genes & Cancer
|
July 7, 2016
The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase
Klaus P Hoeflich, Jane Guan, Kyle A Edgar, et al.
Oncotarget
|
June 10, 2011
p21-activated kinase 1: PAK'ed with potential
Christy C Ong, Adrian M Jubb, Wei Zhou, et al.
Page
of 7